Literature DB >> 10470477

Long-term outcome of transcatheter coil closure of small to large patent ductus arteriosus.

H T Patel1, Q L Cao, J Rhodes, Z M Hijazi.   

Abstract

Coil closure of patent ductus arteriosus (PDA) has become an accepted alternative to surgical closure in most pediatric cardiac centers. However, little is known about the mid-to long-term outcome of this procedure. Therefore, we evaluated the immediate, short-, and long-term outcome of transcatheter coil closure (TCC) of PDA using single or multiple Gianturco coils or the Gianturco-Grifka Vascular Occlusive Device (GGVOD). One hundred forty-nine patients underwent an attempt at TCC of their PDAs at a median age of 2.4 years (2 weeks to 55 years) and median weight of 13.5 kg (2.3-87 kg). There were 33 patients < 1 year of age. The median PDA minimal diameter was 2 mm (0.4-7 mm) with 26 patients whose PDA minimal diameter was > 4 mm. A 4 Fr catheter was used for coil deployment in 136 patients, a 3 Fr in 4, and an 8 Fr in 4 patients who received the GGVOD. A single coil was used in 77 patients and multiple coils (2-6) were used in 66 patients. One hundred forty-six patients had successful closure (142 had immediate complete closure and 4 had residual shunt), 3 patients failed the initial attempt (2 underwent surgical ligation and 1 had a successful second attempt a year later). Of the four patients with residual shunt, three underwent a second procedure with implantation of 1-3 coils resulting in complete closure in all and one patient had spontaneous resolution of the residual shunt. Complications were encountered in nine patients: six had coil migration with successful retrieval in four; two had left pulmonary artery stenosis (2.4 kg and 6.3 kg infants), and one patient had loss of femoral arterial pulse. The median fluoroscopy time was 16 min (2-152 min). One hundred forty-two patients had the procedure as an outpatient, five patients stayed greater than 24 hr, and two of these patients were in hospital for 1 month for noncardiac reasons. At a median follow-up interval of 3.0 years (1 month to 5.1 years), there were no episodes of delayed coil migration, delayed recanalization, thromboembolic episodes, or bacterial endocarditis. Lung perfusion scans performed at a median follow-up interval of 1.6 years in 31 patients who received multiple coils revealed 45% +/- 5% blood flow to the left lung. Long-term follow-up of coil closure of PDA indicates that the technique is safe and effective for most patients with PDA up to a diameter of 7 mm.

Entities:  

Mesh:

Year:  1999        PMID: 10470477     DOI: 10.1002/(SICI)1522-726X(199908)47:4<457::AID-CCD15>3.0.CO;2-A

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  5 in total

Review 1.  Radiographic appearance of pediatric cardiovascular transcatheter devices.

Authors:  Ryan J Williams; Daniel S Levi; John W Moore; M Ines Boechat
Journal:  Pediatr Radiol       Date:  2006-08-05

Review 2.  Catheter interventions in adult patients with congenital heart disease.

Authors:  Timothy S Hornung; Lee N Benson; Peter R McLaughlin
Journal:  Curr Cardiol Rep       Date:  2002-01       Impact factor: 2.931

3.  Aortic thrombus after coil occlusion of a type E patent ductus arteriosus.

Authors:  Juan Villafañe; Frances Vega-Arrillaga
Journal:  Tex Heart Inst J       Date:  2002

4.  Differential pulmonary perfusion scan after percutaneous occlusion of the patent ductus arteriosus: one-decade consecutive longitudinal study from a single institution.

Authors:  Euloge Kouadio Kramoh; Joaquim Miró; Jean-Luc Bigras; Sophie Turpin; Raymond Lambert; Chantal Lapierre; Weidong Jin; Nagib Dahdah
Journal:  Pediatr Cardiol       Date:  2008-04-17       Impact factor: 1.655

5.  Preclosure pressure gradients predict patent ductus arteriosus patients at risk for later left pulmonary artery stenosis.

Authors:  Srinath T Gowda; Shelby Kutty; Makram Ebeid; Athar M Qureshi; Sarah Worley; Larry A Latson
Journal:  Pediatr Cardiol       Date:  2009-04-14       Impact factor: 1.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.